Stockscreener 앱 받기
7.28
0.97%
0.07
시장 영업 전:
7.24
-0.04
-0.55%
전일 마감가:
$7.21
열려 있는:
$7.17
하루 거래량:
2.81M
Relative Volume:
1.20
시가총액:
$1.21B
수익:
$246.03M
순이익/손실:
$-32.00M
주가수익비율:
-34.26
EPS:
-0.2125
순현금흐름:
$-16.78M
1주 성능:
+2.54%
1개월 성능:
+6.59%
6개월 성능:
+56.90%
1년 성능:
+112.87%
1일 변동 폭
$7.01
$7.395
1주일 범위
$6.97
$7.445
52주 변동 폭
$3.14
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
명칭
Xeris Biopharma Holdings Inc
전화
844-445-5704
주소
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
XERS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
7.28 | 1.20B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.21 | 116.79B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.17 | 81.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.70 | 53.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
845.95 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.77 | 37.48B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-08-12 | 재개 | H.C. Wainwright | Buy |
| 2024-11-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2023-08-28 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Craig Hallum | Buy |
| 2021-11-17 | 개시 | SVB Leerink | Outperform |
| 2021-10-29 | 개시 | H.C. Wainwright | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-02-18 | 개시 | Piper Sandler | Overweight |
| 2018-07-16 | 개시 | Jefferies | Buy |
| 2018-07-16 | 개시 | Leerink Partners | Outperform |
| 2018-07-16 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
Have Xeris Biopharma Holdings Insiders Been Selling Stock? - Sahm
Will Xeris Biopharma Holdings Inc. stock pay special dividendsStop Loss & Target Return Focused Stock Picks - Улправда
Will Xeris Biopharma Holdings Inc. stock benefit from sector rotationJuly 2025 Technicals & High Accuracy Buy Signal Tips - Улправда
Squarepoint Ops LLC Purchases 268,572 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (XERS): Assessing Valuation as Investors Back Its Shift to Profitable Specialty Pharma - Sahm
EBIT per share of Xeris Biopharma Holdings, Inc. – LSE:0A8E - TradingView — Track All Markets
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Director John Johnson Sells 135,400 Shares of Xeris Biopharma Ho - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Director Sells $977,588.00 in Stock - MarketBeat
Xeris Biopharma Holdings Insider Sold Shares Worth $977,019, According to a Recent SEC Filing - marketscreener.com
Will Xeris Biopharma Holdings Inc. stock reach all time highs in 20252025 Investor Takeaways & Free Long-Term Investment Growth Plans - DonanımHaber
How Xeris Biopharma’s Shift Toward Profitability and Pipeline Maturity Will Impact Xeris (XERS) Investors - Sahm
Is Xeris Biopharma Holdings Inc. stock a contrarian buyJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory - Finviz
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) - Seeking Alpha
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,000 Shares of Stock - MarketBeat
Insider Sell: Barbara-jean Bormann-kennedy Sells 15,000 Shares o - GuruFocus
Xeris Biopharma (XERS) director reports 15,000-share stock sale - Stock Titan
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Walleye Capital LLC Sells 448,444 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Jump Financial LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
561,700 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Norges Bank - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Coverage Initiated at Barclays - MarketBeat
Barclays Initiates Coverage on Xeris Biopharma Holdings (XERS) w - GuruFocus
Barclays Initiates Xeris Biopharma Holdings at Overweight With $9 Price Target - marketscreener.com
Xeris Biopharma (XERS): Valuation Check After USPTO Notice of Allowance for Weekly Levothyroxine XP-8121 Patent - Sahm
Xeris Biopharma’s (XERS) Positioning Strengthens After Reaching Product Pipeline Milestone - Insider Monkey
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Xeris Biopharma Holdings (XERS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance
Is Xeris Biopharma (XERS) Using XP-8121 Patents to Quietly Redefine Its Long-Term Growth Story? - Sahm
How Xeris Biopharma Holdings Inc. stock performs in weak economy2025 Price Momentum & Verified Trade Idea Suggestions - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock is favored by hedge funds2025 Momentum Check & Fast Gain Stock Tips - Newser
What Wall Street predicts for Xeris Biopharma Holdings Inc. stock price2025 Major Catalysts & Verified High Yield Trade Plans - Newser
How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stockJuly 2025 Opening Moves & Community Verified Watchlist Alerts - Newser
Xeris Biopharma (NASDAQ:XERS) Insider Sells $116,835.67 in Stock - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Shares Down 4.9%Here's Why - MarketBeat
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings - Yahoo Finance
What is Xeris Biopharma Holdings Inc (XERS) Stock Return on Shareholders’ Capital? - Setenews
Risks Still Elevated At These Prices As Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Dive 35% - simplywall.st
Legal & General Group Plc Purchases 392,589 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Is Xeris Biopharma Holdings Inc. stock a safe buy before earningsEarnings Growth Summary & Safe Capital Growth Plans - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsMarket Risk Analysis & Growth Focused Entry Reports - Newser
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS - Investing.com India
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS By Investing.com - Investing.com South Africa
Xeris Biopharma Holdings Director Beth Hecht Sells Shares - TradingView
Officer Hecht Sells 16,667 ($116.8K) Of Xeris Biopharma Holdings Inc [XERS] - TradingView
Oversold Conditions For Xeris Biopharma Holdings (XERS) - Nasdaq
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendations2025 Institutional Moves & Daily Stock Momentum Reports - Newser
A Look at Xeris Biopharma (XERS) Valuation After Patent Progress on Novel Hypothyroidism Therapy - Sahm
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 - MSN
Xeris Biopharma Holdings Inc (XERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.36%
0.33%
자본화:
|
볼륨(24시간):